Kids with spinal muscular atrophy to receive costly drug on compassionate grounds

80 Israeli youngsters suffer from the rare genetic disease.

November 15, 2017 03:25
1 minute read.
Program for children to observe animals

A child looking at the monkeys at the Ramat Gan safari from her hospital bed . (photo credit: RAMAT GAN SAFARI)


Dear Reader,
As you can imagine, more people are reading The Jerusalem Post than ever before. Nevertheless, traditional business models are no longer sustainable and high-quality publications, like ours, are being forced to look for new ways to keep going. Unlike many other news organizations, we have not put up a paywall. We want to keep our journalism open and accessible and be able to keep providing you with news and analysis from the frontlines of Israel, the Middle East and the Jewish World.

As one of our loyal readers, we ask you to be our partner.

For $5 a month you will receive access to the following:

  • A user experience almost completely free of ads
  • Access to our Premium Section
  • Content from the award-winning Jerusalem Report and our monthly magazine to learn Hebrew - Ivrit
  • A brand new ePaper featuring the daily newspaper as it appears in print in Israel

Help us grow and continue telling Israel’s story to the world.

Thank you,

Ronit Hasin-Hochman, CEO, Jerusalem Post Group
Yaakov Katz, Editor-in-Chief


Up to 15 children with severe cases of debilitating spinal muscular atrophy will receive the drug Spinraza, which costs NIS 2 million a year per patient.

The orphan drug will be supplied by its developer, Biogen Inc., for compassionate reasons, Health Minister Ya’acov Litzman told the Finance Committee on Tuesday.

A total of 80 Israeli youngsters suffer from the rare genetic disease, which can significantly improve with the help of the drug. The European Commission approved the drug for marketing six months after the FDA approved it to treat children with SMA. Litzman has instructed all hospitals to provide the drug as an immediate response to SMA for all the serious (type 1) patients suffering from the disease.

SMA is a rare neuromuscular disorder that causes progressive muscle wasting, which often leads to early death. Spinraza (nusinersen) has been found to significantly improve the patient’s functioning. The minister told the committee that he is working on a way to provide treatment to every patient who needs the drug, but did not explain how.

It the drug had to be supplied by the basket of health services for 2018, whose contents are being decided on now, almost one third would have gone to pay for Spinraza. The health basket committee learned that Britain faces a similar dilemma and will supply the drug to some of its affected children.

Join Jerusalem Post Premium Plus now for just $5 and upgrade your experience with an ads-free website and exclusive content. Click here>>

Related Content

May 23, 2019
Regenerative medicine firm CollPlant launches Israel R&D center